These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 15871636)

  • 41. Evolution of secondary hyperparathyroidism after kidney transplantation in patients receiving cinacalcet on dialysis.
    Torregrosa JV; Bergua C; Martinez de Osaba MJ; Oppenheimer F; Campistol JM
    Transplant Proc; 2009; 41(6):2396-8. PubMed ID: 19715931
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Calcium-mediated parathyroid hormone release changes in patients treated with the calcimimetic agent cinacalcet.
    de Francisco AL; Izquierdo M; Cunningham J; Piñera C; Palomar R; Fresnedo GF; Amado JA; Unzueta MG; Arias M
    Nephrol Dial Transplant; 2008 Sep; 23(9):2895-901. PubMed ID: 18424820
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Effect of cinacalcet treatment on vascular arterial stiffness among peritoneal dialysis patients with secondary hyperparathyroidism.
    Chow KM; Szeto CC; Kwan BC; Cheng PM; Pang WF; Leung CB; Li PK
    Nephrology (Carlton); 2014 Jun; 19(6):339-44. PubMed ID: 24589316
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Cinacalcet treatment in dialysis patients with secondary hyperparathyroidism: effects and open issues.
    Drüeke TB
    Ther Apher Dial; 2008 Oct; 12 Suppl 1():S2-12. PubMed ID: 19032522
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Cinacalcet treatment and serum FGF23 levels in haemodialysis patients with secondary hyperparathyroidism.
    Koizumi M; Komaba H; Nakanishi S; Fujimori A; Fukagawa M
    Nephrol Dial Transplant; 2012 Feb; 27(2):784-90. PubMed ID: 21730210
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The Effect of Cinacalcet on Calcific Uremic Arteriolopathy Events in Patients Receiving Hemodialysis: The EVOLVE Trial.
    Floege J; Kubo Y; Floege A; Chertow GM; Parfrey PS
    Clin J Am Soc Nephrol; 2015 May; 10(5):800-7. PubMed ID: 25887067
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The calcimimetic cinacalcet normalizes serum calcium in subjects with primary hyperparathyroidism.
    Shoback DM; Bilezikian JP; Turner SA; McCary LC; Guo MD; Peacock M
    J Clin Endocrinol Metab; 2003 Dec; 88(12):5644-9. PubMed ID: 14671147
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The calcimimetic agent KRN 1493 lowers plasma parathyroid hormone and ionized calcium concentrations in patients with chronic renal failure on haemodialysis both on the day of haemodialysis and on the day without haemodialysis.
    Ohashi N; Uematsu T; Nagashima S; Kanamaru M; Togawa A; Hishida A; Uchida E; Akizawa T; Koshikawa S
    Br J Clin Pharmacol; 2004 Jun; 57(6):726-34. PubMed ID: 15151518
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Cinacalcet HCl: a novel treatment for secondary hyperparathyroidism caused by chronic kidney disease.
    Torres PU
    J Ren Nutr; 2006 Jul; 16(3):253-8. PubMed ID: 16825031
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Cinacalcet: new drug. Secondary hyperparathyroidism: where are the clinical data?
    Prescrire Int; 2006 Jun; 15(83):90-3. PubMed ID: 16764095
    [TBL] [Abstract][Full Text] [Related]  

  • 51. First- and second-generation immunometric PTH assays during treatment of hyperparathyroidism with cinacalcet HCl.
    Martin KJ; Jüppner H; Sherrard DJ; Goodman WG; Kaplan MR; Nassar G; Campbell P; Curzi M; Charytan C; McCary LC; Guo MD; Turner SA; Bushinsky DA
    Kidney Int; 2005 Sep; 68(3):1236-43. PubMed ID: 16105056
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The calcimimetic AMG 073 reduces parathyroid hormone and calcium x phosphorus in secondary hyperparathyroidism.
    Lindberg JS; Moe SM; Goodman WG; Coburn JW; Sprague SM; Liu W; Blaisdell PW; Brenner RM; Turner SA; Martin KJ
    Kidney Int; 2003 Jan; 63(1):248-54. PubMed ID: 12472790
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Pharmacodynamic effects of cinacalcet after kidney transplantation: once- versus twice-daily dose.
    Kamar N; Gennero I; Spataru L; Esposito L; Guitard J; Lavayssière L; Cointault O; Gandia P; Durand D; Rostaing L
    Nephrol Dial Transplant; 2008 Nov; 23(11):3720-6. PubMed ID: 18558623
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Clinical utilization of cinacalcet in hypercalcemic conditions.
    Messa P; Alfieri C; Brezzi B
    Expert Opin Drug Metab Toxicol; 2011 Apr; 7(4):517-28. PubMed ID: 21361849
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Administration of calcimimetics after dialysis: same effectiveness, better gastrointestinal tolerability.
    Esteve Simo V; Moreno-Guzmán F; Martínez Calvo G; Fulquet Nicolas M; Pou Potau M; Macias-Toro J; Duarte-Gallego V; Saurina Sole A; Ramírez-de Arellano Serna M
    Nefrologia; 2015; 35(4):403-9. PubMed ID: 26306967
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Cinacalcet HCl attenuates parathyroid hyperplasia in a rat model of secondary hyperparathyroidism.
    Colloton M; Shatzen E; Miller G; Stehman-Breen C; Wada M; Lacey D; Martin D
    Kidney Int; 2005 Feb; 67(2):467-76. PubMed ID: 15673294
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Tolerance and efficacy of a low dose of the calcimimetic agent cinacalcet in controlling moderate to severe secondary hyperparathyroidism in hemodialysis patients.
    Bashir SO; Omer HA; Aamer MA; Somialy R; Morsy MD
    Saudi J Kidney Dis Transpl; 2015 Nov; 26(6):1135-41. PubMed ID: 26586050
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Cinacalcet and achievement of the NKF/K-DOQI recommended target values for bone and mineral metabolism in real-world clinical practice--the ECHO observational study.
    Ureña P; Jacobson SH; Zitt E; Vervloet M; Malberti F; Ashman N; Leavey S; Rix M; Os I; Saha H; Ryba M; Bencova V; Baños A; Zani V; Fouque D
    Nephrol Dial Transplant; 2009 Sep; 24(9):2852-9. PubMed ID: 19369690
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Mineral metabolism in renal transplant recipients discontinuing cinacalcet at the time of transplantation: a prospective observational study.
    Evenepoel P; Sprangers B; Lerut E; Bammens B; Claes K; Kuypers D; Meijers B; Vanrenterghem Y
    Clin Transplant; 2012; 26(3):393-402. PubMed ID: 22007637
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Cinacalcet hydrochloride for the treatment of hyperparathyroidism.
    Verheyen N; Pilz S; Eller K; Kienreich K; Fahrleitner-Pammer A; Pieske B; Ritz E; Tomaschitz A
    Expert Opin Pharmacother; 2013 Apr; 14(6):793-806. PubMed ID: 23452174
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.